Asenapine for bipolar disorder

Thomas Scheidemantel,1 Irina Korobkova,2 Soham Rej,3,4 Martha Sajatovic1,2 1University Hospitals Case Medical Center, 2Case Western Reserve University School of Medicine, Cleveland, OH, USA; 3Department of Psychiatry, University of Toronto, Toronto, ON, 4Geri PARTy Research Group, Jewish General Ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Scheidemantel T, Korobkova I, Rej S, Sajatovic M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	asenapine bipolar manic episode mixed episode depressive features safety tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0084447278414370b59455999c7217e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0084447278414370b59455999c7217e8
record_format	dspace
spelling	oai:doaj.org-article:0084447278414370b59455999c7217e82021-12-02T00:33:51ZAsenapine for bipolar disorder1178-2021https://doaj.org/article/0084447278414370b59455999c7217e82015-12-01T00:00:00Zhttps://www.dovepress.com/asenapine-for-bipolar-disorder-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Thomas Scheidemantel,1 Irina Korobkova,2 Soham Rej,3,4 Martha Sajatovic1,2 1University Hospitals Case Medical Center, 2Case Western Reserve University School of Medicine, Cleveland, OH, USA; 3Department of Psychiatry, University of Toronto, Toronto, ON, 4Geri PARTy Research Group, Jewish General Hospital, Montreal, QC, Canada Abstract: Asenapine (Saphris®) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the treatment of schizophrenia in adults, as well as the treatment of acute manic or mixed episodes of bipolar I in both adult and pediatric populations. Asenapine is a tetracyclic drug with antidopaminergic and antiserotonergic activity with a unique sublingual route of administration. In this review, we examine and summarize the available literature on the safety, efficacy, and tolerability of asenapine in the treatment of bipolar disorder (BD). Data from randomized, double-blind trials comparing asenapine to placebo or olanzapine in the treatment of acute manic or mixed episodes showed asenapine to be an effective monotherapy treatment in clinical settings; asenapine outperformed placebo and showed noninferior performance to olanzapine based on improvement in the Young Mania Rating Scale scores. There are limited data available on the use of asenapine in the treatment of depressive symptoms of BD, or in the maintenance phase of BD. The available data are inconclusive, suggesting the need for more robust data from prospective trials in these clinical domains. The most commonly reported adverse effect associated with use of asenapine is somnolence. However, the somnolence associated with asenapine use did not cause significant rates of discontinuation. While asenapine was associated with weight gain when compared to placebo, it appeared to be modest when compared to other atypical antipsychotics, and its propensity to cause increases in hemoglobin A1c or serum lipid levels appeared to be similarly modest. Asenapine does not appear to cause any clinically significant QTc prolongation. The most commonly reported extra-pyramidal symptom associated with asenapine was akathisia. Overall, asenapine appears to be a relatively well-tolerated atypical antipsychotic, effective in the treatment of acute manic and mixed episodes of BD. Keywords: asenapine, bipolar, manic episode, mixed episode, depressive features, safety, tolerabilityScheidemantel TKorobkova IRej SSajatovic MDove Medical Pressarticleasenapinebipolarmanic episodemixed episodedepressive featuressafetytolerabilityNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss Issue 1, Pp 3007-3017 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	asenapine bipolar manic episode mixed episode depressive features safety tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	asenapine bipolar manic episode mixed episode depressive features safety tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Scheidemantel T Korobkova I Rej S Sajatovic M Asenapine for bipolar disorder
description	Thomas Scheidemantel,1 Irina Korobkova,2 Soham Rej,3,4 Martha Sajatovic1,2 1University Hospitals Case Medical Center, 2Case Western Reserve University School of Medicine, Cleveland, OH, USA; 3Department of Psychiatry, University of Toronto, Toronto, ON, 4Geri PARTy Research Group, Jewish General Hospital, Montreal, QC, Canada Abstract: Asenapine (Saphris®) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the treatment of schizophrenia in adults, as well as the treatment of acute manic or mixed episodes of bipolar I in both adult and pediatric populations. Asenapine is a tetracyclic drug with antidopaminergic and antiserotonergic activity with a unique sublingual route of administration. In this review, we examine and summarize the available literature on the safety, efficacy, and tolerability of asenapine in the treatment of bipolar disorder (BD). Data from randomized, double-blind trials comparing asenapine to placebo or olanzapine in the treatment of acute manic or mixed episodes showed asenapine to be an effective monotherapy treatment in clinical settings; asenapine outperformed placebo and showed noninferior performance to olanzapine based on improvement in the Young Mania Rating Scale scores. There are limited data available on the use of asenapine in the treatment of depressive symptoms of BD, or in the maintenance phase of BD. The available data are inconclusive, suggesting the need for more robust data from prospective trials in these clinical domains. The most commonly reported adverse effect associated with use of asenapine is somnolence. However, the somnolence associated with asenapine use did not cause significant rates of discontinuation. While asenapine was associated with weight gain when compared to placebo, it appeared to be modest when compared to other atypical antipsychotics, and its propensity to cause increases in hemoglobin A1c or serum lipid levels appeared to be similarly modest. Asenapine does not appear to cause any clinically significant QTc prolongation. The most commonly reported extra-pyramidal symptom associated with asenapine was akathisia. Overall, asenapine appears to be a relatively well-tolerated atypical antipsychotic, effective in the treatment of acute manic and mixed episodes of BD. Keywords: asenapine, bipolar, manic episode, mixed episode, depressive features, safety, tolerability
format	article
author	Scheidemantel T Korobkova I Rej S Sajatovic M
author_facet	Scheidemantel T Korobkova I Rej S Sajatovic M
author_sort	Scheidemantel T
title	Asenapine for bipolar disorder
title_short	Asenapine for bipolar disorder
title_full	Asenapine for bipolar disorder
title_fullStr	Asenapine for bipolar disorder
title_full_unstemmed	Asenapine for bipolar disorder
title_sort	asenapine for bipolar disorder
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/0084447278414370b59455999c7217e8
work_keys_str_mv	AT scheidemantelt asenapineforbipolardisorder AT korobkovai asenapineforbipolardisorder AT rejs asenapineforbipolardisorder AT sajatovicm asenapineforbipolardisorder
_version_	1718403594637541376

Asenapine for bipolar disorder

Ejemplares similares